Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509749 | 0.81 | ALOX15 (0.43) | GAAAGTR1HSD17B10ALOX15MAPT | |
| SCHEMBL10764381 | 0.80 | GAA (0.51) | GAAAGTR1HSD17B10MAPTALOX12 | |
| SCHEMBL5507339 | 0.79 | GAA (0.49) | GAAHSD17B10ALOX15MAPTALOX12 | |
| SCHEMBL14509701 | 0.76 | ALOX15 (0.39) | GAAAGTR1HSD17B10ALOX15ALOX12 | |
| SCHEMBL18761542 | 0.72 | ALOX15 (0.47) | GAAHSD17B10ALOX15MAPTMEN1 | |
| SCHEMBL20829562 | 0.72 | ALOX15 (0.47) | GAAHSD17B10ALOX15MAPTMEN1 | |
| SCHEMBL4253259 | 0.72 | ALOX15 (0.47) | GAAHSD17B10ALOX15MAPTMEN1 | |
| SCHEMBL14509665 | 0.72 | MAPT (0.42) | GAAAGTR1ALOX15MAPTALOX12 | |
| SCHEMBL5508743 | 0.71 | ALOX12 (0.54) | GAAMAPTALOX12TDP1MEN1 | |
| SCHEMBL31444391 | 0.69 | CHRNB2 (0.44) | GAAAGTR1SMN1; SMN2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047676-B1 | SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | HARVARD COLLEGE (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1047676-B1 | SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | HARVARD COLLEGE (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6992079-B2 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | President Fellows of Harvard College (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1044190-B1 | SYNTHESIS OF 11-ARYL-5,6-DIHYDRO-11H-DIBENZ(B,E)AZEPINES | JOHNSON MATTHEY PHARMACEUTICAL (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002486-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-01 | — | — | US | disclosed |
| US-20030191111-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-20030134842-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | BRUGNARA CARLO (US) | 2003-07-17 | — | — | US | disclosed |
| US-6534497-B1 | Specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by | NUCHEM PHARMACEUTICALS, INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| EP-1032394-A1 | USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026628-A1 | USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002486-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | MKI67, BOD1L1, BRCA1 | GAA 650/4885AGTR1 2493/4885HSD17B10 217/4885 |
| US-20030191111-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | MKI67, BOD1L1, BRCA1 | GAA 650/4885AGTR1 2493/4885HSD17B10 217/4885 |
| US-20030134842-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | KCNN2, KCNN1, KCNN3 | GAA 415/4885AGTR1 3165/4885HSD17B10 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.